Noll L Campbell1,2,3,4,5, Richard J Holden2,3,4,5, Qing Tang6, Malaz A Boustani2,3,4,5, Evgenia Teal7, Jennifer Hillstrom3, Wanzhu Tu2,6, Daniel O Clark2,3,4, Christopher M Callahan2,3,4. 1. Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, Indiana, USA. 2. Center for Aging Research, Regenstrief Institute, Inc., Indianapolis, Indiana, USA. 3. Sandra Eskenazi Center for Brain Care Innovation, Eskenazi Health, Indianapolis, Indiana, USA. 4. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. 5. Center for Health Innovation and Implementation Science, Indiana University School of Medicine, Indianapolis, Indiana, USA. 6. Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA. 7. Data Core, Regenstrief Institute, Inc., Indianapolis, Indiana, USA.
Abstract
OBJECTIVE: To test the impact of a multicomponent behavioral intervention to reduce the use of high-risk anticholinergic medications in primary care older adults. DESIGN: Cluster-randomized controlled trial. SETTING AND PARTICIPANTS: Ten primary care clinics within Eskenazi Health in Indianapolis. INTERVENTION: The multicomponent intervention included provider- and patient-focused components. The provider-focused component was computerized decision support alerting of the presence of a high-risk anticholinergic and offering dose- and indication-specific alternatives. The patient-focused component was a story-based video providing education and modeling an interaction with a healthcare provider resulting in a medication change. Alerts within the medical record triggered staff to play the video for a patient. Our design intended for parallel, independent priming of both providers and patients immediately before an outpatient face-to-face interaction. MEASUREMENT: Medication orders were extracted from the electronic medical record system to evaluate the prescribing behavior and population prevalence of anticholinergic users. The intervention was introduced April 1, 2019, through March 31, 2020, and a preintervention observational period of April 1, 2018, through March 31, 2019, facilitated difference in difference comparisons. RESULTS: A total of 552 older adults had visits at primary care sites during the study period, with mean age of 72.1 (SD 6.4) years and 45.3% African American. Of the 259 provider-focused alerts, only three (1.2%) led to a medication change. Of the 276 staff alerts, 4.7% were confirmed to activate the patient-focused intervention. The intervention resulted in no significant differences in either the number of discontinue orders for anticholinergics (intervention: two additional orders; control: five fewer orders, p = 0.7334) or proportion of the population using anticholinergics following the intervention (preintervention: 6.2% and postintervention: 5.1%, p = 0.6326). CONCLUSION: This multicomponent intervention did not reduce the use of high-risk anticholinergics in older adults receiving primary care. Improving nudges or a policy-focused component may be necessary to reduce use of high-risk medications.
OBJECTIVE: To test the impact of a multicomponent behavioral intervention to reduce the use of high-risk anticholinergic medications in primary care older adults. DESIGN: Cluster-randomized controlled trial. SETTING AND PARTICIPANTS: Ten primary care clinics within Eskenazi Health in Indianapolis. INTERVENTION: The multicomponent intervention included provider- and patient-focused components. The provider-focused component was computerized decision support alerting of the presence of a high-risk anticholinergic and offering dose- and indication-specific alternatives. The patient-focused component was a story-based video providing education and modeling an interaction with a healthcare provider resulting in a medication change. Alerts within the medical record triggered staff to play the video for a patient. Our design intended for parallel, independent priming of both providers and patients immediately before an outpatient face-to-face interaction. MEASUREMENT: Medication orders were extracted from the electronic medical record system to evaluate the prescribing behavior and population prevalence of anticholinergic users. The intervention was introduced April 1, 2019, through March 31, 2020, and a preintervention observational period of April 1, 2018, through March 31, 2019, facilitated difference in difference comparisons. RESULTS: A total of 552 older adults had visits at primary care sites during the study period, with mean age of 72.1 (SD 6.4) years and 45.3% African American. Of the 259 provider-focused alerts, only three (1.2%) led to a medication change. Of the 276 staff alerts, 4.7% were confirmed to activate the patient-focused intervention. The intervention resulted in no significant differences in either the number of discontinue orders for anticholinergics (intervention: two additional orders; control: five fewer orders, p = 0.7334) or proportion of the population using anticholinergics following the intervention (preintervention: 6.2% and postintervention: 5.1%, p = 0.6326). CONCLUSION: This multicomponent intervention did not reduce the use of high-risk anticholinergics in older adults receiving primary care. Improving nudges or a policy-focused component may be necessary to reduce use of high-risk medications.
Authors: Robyn Tamblyn; Allen Huang; Robert Perreault; André Jacques; Denis Roy; James Hanley; Peter McLeod; Réjean Laprise Journal: CMAJ Date: 2003-09-16 Impact factor: 8.262
Authors: Amy J Davidoff; G Edward Miller; Eric M Sarpong; Eunice Yang; Nicole Brandt; Donna M Fick Journal: J Am Geriatr Soc Date: 2015-03-06 Impact factor: 5.562
Authors: Shelly L Gray; Melissa L Anderson; Sascha Dublin; Joseph T Hanlon; Rebecca Hubbard; Rod Walker; Onchee Yu; Paul K Crane; Eric B Larson Journal: JAMA Intern Med Date: 2015-03 Impact factor: 21.873
Authors: Richard J Holden; Preethi Srinivas; Noll L Campbell; Daniel O Clark; Kunal S Bodke; Youngbok Hong; Malaz A Boustani; Denisha Ferguson; Christopher M Callahan Journal: Res Social Adm Pharm Date: 2018-03-06
Authors: Anja Rieckert; David Reeves; Attila Altiner; Eva Drewelow; Aneez Esmail; Maria Flamm; Mark Hann; Tim Johansson; Renate Klaassen-Mielke; Ilkka Kunnamo; Christin Löffler; Giuliano Piccoliori; Christina Sommerauer; Ulrike S Trampisch; Anna Vögele; Adrine Woodham; Andreas Sönnichsen Journal: BMJ Date: 2020-06-18
Authors: Ephrem Abebe; Noll L Campbell; Daniel O Clark; Wanzhu Tu; Jordan R Hill; Addison B Harrington; Gracen O'Neal; Kimberly S Trowbridge; Christian Vallejo; Ziyi Yang; Na Bo; Alexxus Knight; Khalid A Alamer; Allie Carter; Robin Valenzuela; Philip Adeoye; Malaz A Boustani; Richard J Holden Journal: Res Social Adm Pharm Date: 2020-10-22
Authors: Arnold G Vulto; Isabelle Huys; Yannick Vandenplas; Steven Simoens; Florian Turk Journal: Appl Health Econ Health Policy Date: 2022-08-16 Impact factor: 3.686